Autopsy report · NCT05142228

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

“Low enrollment rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 5 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Maryland, Baltimore

Sponsor type

University, hospital or other

Conditions

Trigeminal Neuropathy

Interventions

Erenumab-Aooe; Placebo

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
  “Low rate of enrollment” (97% match in meaning)
• Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
  “Low enrollment rates.” (91% match in meaning)
• The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding
  “Low enroll rate” (90% match in meaning)
• Tocilizumab for the Treatment of Behcet's Syndrome
  “low enrollment” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.